Dechert Advises Royalty Pharma in Acquisition of Royalty Interest in Seltorexant from Minerva Neurosciences
January 20, 2021
Dechert is advising Royalty Pharma plc on IP-related matters in its agreement to acquire the royalty interest in Seltorexant from Minerva Neurosciences, Inc. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson. Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system diseases.
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
The Dechert team advising Royalty Pharma included intellectual property partner Carl A. Morales, Ph.D., associate Blaine M. Hackman, Ph.D. and patent agent Michael G. Manas, Ph.D.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for all clients.
